Information is shared for educational purposes only
No hidden fees, no surprise costs
They can help rule out other conditions, such as gastroesophageal reflux disease (GERD), suggest a change to your Wegovy dosing schedule , or recommend a different treatment
In addition to weight reduction, the Phase 2 trial reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in blood pressure Favourable changes in lipid profiles Reductions in fasting glucose and insulin resistance Increases in heart rate were also observed, consistent with findings seen with other incretin-based therapies These findings suggest that retatrutide may offer broader metabolic benefits beyond weight loss alone, which is particularly relevant for patients with obesity-related comorbidities such as type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), or elevated cardiovascular risk
Zhang Q, Delessa CT, Augustin R, et al
